A Marketplace Breakout, a Biotech Catalyst Trade, and a Foundry Comeback Signal

One digital marketplace is proving its model with clean earnings and another new high. One biotech name is moving on an outbreak-linked catalyst that still needs real clinical progress, while one chipmaker just picked up the kind of customer signal its foundry turnaround needed. We’ll show you where to buy, where to trade, and where the breakout still has legs.

A small biotech just passed 75% enrollment in a late-stage clinical trial at some of the top heart centers in the U.S. - Cleveland Clinic, Mayo Clinic, Mass General, and Columbia.

The company's drug already showed clear, measurable results in a mid-stage trial published in a leading medical journal. Now it's going after a recurring heart condition where the only approved treatment is a weekly injection expected to do nearly $950 million in sales this year - and 82% of patients still aren't being treated.

Wall Street already has two Buy ratings on the stock with price targets 3-4x the current share price.

Get the full report

This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

Futures are slipping after last week’s strong run, with oil jumping as Trump rejected Iran’s latest peace proposal. Traders are still betting on market resilience, but this week’s inflation data now carries extra weight with war-driven price pressure back in focus.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• Constellation Energy Corporation [CEG]
• Barrick Mining Corporation [B]
• Circle Internet Group, Inc. [CRCL]
• Fox Corporation [FOX]

Earnings (Aftermarket):
• Simon Property Group, Inc. [SPG]
• AST SpaceMobile, Inc. [ASTS]

Economic Reports:
• Existing home sales (April): 10:00 am

A senior executive at a trading firm sold $1.5 million worth of stock near its 52-week high, while two insiders at a rare earths name unloaded another $2.0 million after a massive 219% one-year run.

If you’re not an Elite Trade Club Insider, you’re missing out on where leadership is locking in gains after the market already did the heavy lifting.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Openlane Inc (NYSE: OPLN) just gave investors another reason to trust the digital auto auction model. The company reported first-quarter revenue of $527.9 million, ahead of the $497.1 million analysts expected, while EPS came in at $0.35, beating the $0.32 consensus. That is not a massive beat, but it is clean enough to matter for a stock already trading near a fresh 52-week high.

The bigger story is consistency. Openlane has been benefiting from its digital-first approach in used and salvage vehicle auctions, and the market is starting to reward that execution.

The stock is up about 30% year to date and more than 70% over the past year, which tells you investors are treating this less like a cyclical auto-adjacent name and more like a scaled marketplace with improving earnings power.

This is still tied to dealer activity, used vehicle supply, and broader auto demand. But Openlane’s recent results show it is doing more than riding a one-quarter bump. Revenue beat, earnings beat, and another new high together give the stock a stronger quality signal.

My Take For You: Openlane is proving that its marketplace model can still grow even in a choppy auto environment. This is a cleaner small-cap momentum story than it looks at first glance.

My Verdict: Buy this. The risk is that dealer volumes soften and slow the earnings momentum that is driving the rerating.

Moderna Inc (NASDAQ: MRNA) is back in focus after a U.S. passenger from the MV Hondius cruise ship tested positive for the Andes strain of hantavirus. The stock rose about 8% premarket after the news, building on a sharp move from Friday, as investors connected the outbreak headline to Moderna’s infectious-disease pipeline.

The company confirmed last week that it is exploring a hantavirus treatment as part of its broader emerging infectious-disease efforts. That matters because Moderna badly needs investors to see it as more than a COVID-era vaccine story.

The stock is up more than 111% over the past year, but it still trades far below its prior highs, and every credible pipeline expansion matters for sentiment.

The problem is timing. Moderna described the hantavirus work as early-stage and ongoing, which means the market is reacting to potential, not near-term revenue. A disease headline can move the stock quickly, but it does not automatically create a commercial product, a regulatory path, or a durable earnings stream.

My Take For You: This gives Moderna a useful reminder that its platform still has optionality beyond its older vaccine story. But this is a catalyst trade first and a proven revenue story later.

My Verdict: Trade this. The risk is that the outbreak headline fades before Moderna can show real clinical or commercial progress.

After analyzing thousands of companies, our analysts pinpointed the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.

This newly released report explains why these five could be positioned for major moves in the year ahead.

While results aren’t guaranteed, previous reports uncovered gains as high as +175%, +498%, and +673%.

Access the free report before midnight.

See the 5 Stocks Set to Double

*Results may not represent all stock picks and may reflect partially closed positions. Investing involves risk, and past performance does not guarantee future results. This is not financial advice.

Intel Corp (NASDAQ: INTC) just picked up one of the biggest credibility signals it could have asked for. Reports say the company has reached a preliminary chipmaking agreement with Apple, giving Intel another high-profile customer win as it tries to rebuild its foundry reputation.

The stock jumped on the news, adding to a massive rally that has already taken shares up more than 460% over the past year. This matters because Intel’s turnaround depends on more than strong earnings prints. It needs customers to believe its manufacturing roadmap is real.

A deal with Apple would carry serious symbolic weight because Apple moved away from Intel-designed processors years ago and has relied heavily on TSMC for its custom silicon supply chain. If Apple is now willing to broaden manufacturing exposure through Intel, that is a major vote of confidence.

There are still unanswered questions. The reports do not make clear which products Intel would manufacture, how much volume is involved, or when production would begin. But after recent momentum from government backing, Nvidia, SoftBank, and stronger chip demand, this adds another layer to the recovery case.

My Take For You: Intel’s foundry comeback is no longer just a policy-backed story. Big-name customer interest is starting to show up, and Apple would be the most important validation yet.

My Verdict: Buy the breakout. The risk is that the Apple deal stays small or takes too long to turn into meaningful foundry revenue.

Dole is slipping before earnings because the setup looks tight. Analysts expect $0.35 in EPS on $2.23 billion in revenue, but the real issue is margins. This is a fresh-produce business with gross margin around 7.8%, so higher shipping costs, fuel, insurance, and weaker European demand can hit earnings fast.

There is still upside if management protects EBITDA, but this is not an easy tape for a low-margin global distributor.

Everpure is moving higher even after a $10 million insider sale, which tells you the market is still focused on the AI data-storage story. Revenue grew 16% last year to $3.7 billion, Q4 sales rose 20%, and fiscal 2027 guidance points to 17% to 20% growth.

The risk is margin pressure. Component costs are spiking, and management is absorbing some of that pain instead of fully passing it through. That can win customers, but it can also squeeze profits.

MaxLinear is still climbing because the AI infrastructure re-rating has not cooled off. The stock has exploded from the low $20s to around $100, helped by strong Q1 results, better Q2 guidance, and a wave of upgrades from firms like Needham, Roth, Northland, Stifel, Loop, and Deutsche Bank.

This is now a full momentum stock. The AI optics story is real, with new products aimed at 1.6T data-center interconnects and AI inference bottlenecks, but the valuation has already moved hard.

One drug company is making nearly $1 billion a year treating a recurring heart condition with a weekly injection - and 82% of eligible patients still aren't on therapy.

Now a small biotech is developing an oral alternative. Its mid-stage trial already showed real, measurable results published in a top medical journal. And its late-stage trial is 75%+ enrolled at Cleveland Clinic, Mayo Clinic, and Mass General.

The market is proven. The unmet need is massive. And late-stage data could be months away.

Read the full breakdown here

This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.